DUBLIN–(BUSINESS WIRE)–Feb 8, 2021–
The "Global Dry Eye Clinical Trial Pipeline Highlights – 2021" report has been added to ResearchAndMarkets.com’s offering.
This report provides the most up-to-date information on key pipeline products in the global Dry Eye market. It covers emerging therapies for Dry Eye in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages:
The report provides Dry Eye pipeline products by clinical trial stages including both early and late stage development – phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Dry Eye pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.
Company:
The report provides Dry Eye pipeline products by the company.
Short-term Launch Highlights:
Find out which Dry Eye pipeline products will be launched in the US and Ex-US till 2025.
SUMMARY:
- Dry Eye phase 3 clinical trial pipeline products
- Dry Eye phase 2 clinical trial pipeline products
- Dry Eye phase 1 clinical trial pipeline products
- Dry Eye preclinical research pipeline products
- Dry Eye discovery stage pipeline products
- Dry Eye pipeline products short-term launch highlights
Key Topics Covered:
1. Dry Eye Pipeline by Stages
2. Dry Eye Phase 3 Clinical Trial Insights
3. Dry Eye Phase 2 Clinical Trial Insights
4. Dry Eye Phase 1 Clinical Trial Insights
5. Dry Eye Preclinical Research Insights
6. Dry Eye Discovery Stage Insights
7. Appendix
8. Research Methodology
Countries Covered
- Global
- Europe
- US
- Germany
- France
- UK
- Spain
- Italy
- Japan
For more information about this report visit https://www.researchandmarkets.com/r/kfz7mg
View source version on businesswire.com:https://www.businesswire.com/news/home/20210208005574/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected] For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: OPTICAL HEALTH CLINICAL TRIALS
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 02/08/2021 10:41 AM/DISC: 02/08/2021 10:41 AM
http://www.businesswire.com/news/home/20210208005574/en
